Literature DB >> 20056546

2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.

Aleem Gangjee1, Hiteshkumar D Jain, Jaclyn Phan, Xin Guo, Sherry F Queener, Roy L Kisliuk.   

Abstract

A novel classical antifolate N-{4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)thio]-benzoyl}-l-glutamic acid 5 and 11 nonclassical antifolates 6-16 were designed, synthesized, and evaluated as inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS). The nonclassical compounds 6-16 were synthesized from 20 via oxidative addition of substituted thiophenols using iodine. Peptide coupling of the intermediate acid 21 followed by saponification gave the classical analog 5. Compound 5 is the first example, to our knowledge, of a 2,4-diamino furo[2,3-d]pyrimidine classical antifolate that has inhibitory activity against both human DHFR and human TS. The classical analog 5 was a nanomolar inhibitor and remarkably selective inhibitor of Pneumocystis carinii DHFR and Mycobacterium avium DHFR at 263-fold and 2107-fold, respectively, compared to mammalian DHFR. The nonclassical analogs 6-16 were moderately potent against pathogen DHFR or TS. This study shows that the furo[2,3-d]pyrimidine scaffold is conducive to dual human DHFR-TS inhibitory activity and to high potency and selectivity for pathogen DHFR. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20056546      PMCID: PMC2818873          DOI: 10.1016/j.bmc.2009.11.029

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  29 in total

Review 1.  The renewed potential for folate antagonists in contemporary cancer chemotherapy.

Authors:  E M Berman; L M Werbel
Journal:  J Med Chem       Date:  1991-02       Impact factor: 7.446

2.  Inhibition of murine thymidylate synthase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin.

Authors:  J B Hynes; S A Patil; A Tomazic; A Kumar; A Pathak; X H Tan; X Q Li; M Ratnam; T J Delcamp; J H Freisheim
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

Review 3.  Chemistry and biological activity of antifolates.

Authors:  A Rosowsky
Journal:  Prog Med Chem       Date:  1989

Review 4.  Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.

Authors:  Patrick Willemot; Marina B Klein
Journal:  Expert Rev Anti Infect Ther       Date:  2004-08       Impact factor: 5.091

Review 5.  Structure, dynamics, and catalytic function of dihydrofolate reductase.

Authors:  Jason R Schnell; H Jane Dyson; Peter E Wright
Journal:  Annu Rev Biophys Biomol Struct       Date:  2004

6.  Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.

Authors:  E M Grivsky; S Lee; C W Sigel; D S Duch; C A Nichol
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

7.  Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid.

Authors:  R L Kisliuk; D Strumpf; Y Gaumont; R P Leary; L Plante
Journal:  J Med Chem       Date:  1977-11       Impact factor: 7.446

8.  Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.

Authors:  J Galivan; Z Nimec; M Rhee
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

9.  The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.

Authors:  J Galivan; M S Rhee; T B Johnson; R Dilwith; M G Nair; M Bunni; D G Priest
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

10.  Expression of human thymidylate synthase in Escherichia coli.

Authors:  V J Davisson; W Sirawaraporn; D V Santi
Journal:  J Biol Chem       Date:  1989-06-05       Impact factor: 5.157

View more
  6 in total

1.  Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase.

Authors:  Vivian Cody; Jim Pace; Jennifer Piraino; Sherry F Queener
Journal:  J Struct Biol       Date:  2011-06-13       Impact factor: 2.867

2.  Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping.

Authors:  Darren W Begley; Suxin Zheng; Gabriele Varani
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

3.  Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.

Authors:  Michelle de Paula Reis; Daniely Alves de Lima; Karoline Bach Pauli; Carlos Eduardo Linhares Andreotti; André Luiz Soares de Moraes; Daniela Dib Gonçalves; Italmar Teodorico Navarro; Paulo Sérgio Alves Bueno; Flavio Augusto Vicente Seixas; Arquimedes Gasparotto Junior; Emerson Luiz Botelho Lourenço
Journal:  Parasitol Res       Date:  2018-03-17       Impact factor: 2.289

Review 4.  Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.

Authors:  Madalyn M McFarland; Sydney J Zach; Xiaofang Wang; Lakshmi-Prasad Potluri; Andrew J Neville; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.

Authors:  Yu-Shan Cheng; James C Sacchettini
Journal:  Biochemistry       Date:  2016-02-05       Impact factor: 3.162

6.  An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes.

Authors:  Mahreen Arooj; Sugunadevi Sakkiah; Guang ping Cao; Keun Woo Lee
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.